Drug Database
AC
acellular pertussis vaccine (pertactin / 69kDa protein, SBL / Infanrix)
✓ ApprovedGSK · · Vaccine
What is acellular pertussis vaccine?
acellular pertussis vaccine is a vaccine developed by GSK. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.
Drug Profile
| Brand Names | pertactin, 69kDa protein, SBL, Infanrix |
| Company | GSK |
| Drug Class | Vaccine |
| Molecular Target | , , , , |
| Route | Injectable (Others), Intramuscular (IM) Injection |
| Status | Approved |
Sources: ClinicalTrials.gov, GSK
Mechanism of Action
Molecular Targets
acellular pertussis vaccine acts on 5 molecular targets:
| () | |
| () | |
| () | |
| () | |
| () |
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.
Therapeutic Indications
acellular pertussis vaccine is developed for 3 unique indications across 1 therapeutic area.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Infections and infestations | Diphtheria | ✓ Approved |
| Infections and infestations | Pertussis | ✓ Approved |
| Infections and infestations | Tetanus | ✓ Approved |
Related Research Articles
Unable to load articles right now.